![](https://www.diabetesnews.com/wp-content/uploads/2013/06/insulin-150x150.jpeg)
Last week, Eli Lilly and Company announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes.